Integra LifeSciences (NASDAQ:IART) Sets New 52-Week Low at $31.53

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) hit a new 52-week low during trading on Thursday . The stock traded as low as $31.53 and last traded at $31.57, with a volume of 232579 shares changing hands. The stock had previously closed at $31.94.

Wall Street Analysts Forecast Growth

IART has been the topic of several analyst reports. Truist Financial cut their price target on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a report on Friday, March 1st. Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price for the company in a report on Wednesday, April 3rd. StockNews.com lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Friday, April 5th. Finally, JMP Securities reduced their price objective on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research note on Thursday, February 29th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $44.89.

Integra LifeSciences Price Performance

The firm has a 50 day moving average price of $36.85 and a two-hundred day moving average price of $39.08. The company has a market cap of $2.25 billion, a P/E ratio of 34.55, a P/E/G ratio of 0.95 and a beta of 1.12. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.01). The business had revenue of $397.00 million during the quarter, compared to analysts’ expectations of $399.30 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. Integra LifeSciences’s revenue for the quarter was down .3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.94 EPS. On average, analysts predict that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Large investors have recently made changes to their positions in the stock. Signaturefd LLC lifted its holdings in Integra LifeSciences by 248.5% during the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock worth $25,000 after purchasing an additional 415 shares in the last quarter. Hexagon Capital Partners LLC increased its position in shares of Integra LifeSciences by 123.3% during the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock valued at $29,000 after buying an additional 370 shares during the period. Itau Unibanco Holding S.A. lifted its holdings in shares of Integra LifeSciences by 469.5% in the second quarter. Itau Unibanco Holding S.A. now owns 746 shares of the life sciences company’s stock worth $31,000 after buying an additional 615 shares in the last quarter. Gladius Capital Management LP bought a new position in shares of Integra LifeSciences in the third quarter valued at approximately $47,000. Finally, Valley National Advisers Inc. purchased a new position in Integra LifeSciences during the first quarter valued at approximately $63,000. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.